Logo-bi
Bioimpacts. 2019;9(3): 123-127. doi: 10.15171/bi.2019.16
PMID: 31508327        PMCID: PMC6726747

Editorial

Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates

Mostafa Akbarzadeh Khiavi 1,2 ORCID, Azam Safary 2,3 ORCID, Mohammad Hossein Somi 1 * ORCID

Cited by CrossRef: 23

1- Lotfi F, Akbarzadeh-Khiavi M, Lotfi Z, Rahbarnia L, Safary A, Zarredar H, Baghbanzadeh A, Naghili B, Baradaran B. Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. Infection. 2021;49(6):1133 [Crossref]
2- Akbarzadeh Khiavi M, Safary A, Barar J, Farzi-Khajeh H, Barzegari A, Mousavi R, Somi M, Omidi Y. PEGylated gold nanoparticles-ribonuclease induced oxidative stress and apoptosis in colorectal cancer cells. Bioimpacts. 2019;10(1):27 [Crossref]
3- Jin K, Chen B, Liu Y, Lan H, Yan J. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int. 2021;21(1) [Crossref]
4- Olfati A, Safary A, Akbarzadeh-Khiavi M, Adibkia K. Recent advances in protein corona and practical applications of nanoparticle-based therapeutic agents. Journal of Drug Delivery Science and Technology. 2023;87:104844 [Crossref]
5- Alizadeh S, Esmaeili A, Barar J, Omidi Y. Optogenetics: A new tool for cancer investigation and treatment. Bioimpacts. 2022;12(4):295 [Crossref]
6- Balakarthikeyan J, Mayakrishnan V, Kannappan P, Al-Ghamdi S, Alrudian N, Alqahtani M, El-Bidawy M, Albasheer K, Gamil S, Alsanousi N, Ramesh T. Cetuximab-conjugated andrographolide loaded chitosan-pectin composite nanoparticles for colorectal cancer. Journal of King Saud University - Science. 2024;36(7):103261 [Crossref]
7- Yang X, Luo Z, Fang D, Chen Q, Peng N, Fang H, Zou T. Hollow Copper Sulfide Nanocubes Loaded with Pt(IV) Complexes for Cancer Multimodal Therapy. Langmuir. 2024;40(43):22875 [Crossref]
8- Lucía C. Future directions in cancer immunotherapy with monoclonal antibodies. RRP. 2022;8(4):101 [Crossref]
9- Chen R, Huang Y, Wang L, Zhou J, Tan Y, Peng C, Yang P, Peng W, Li J, Gu Q, Sheng Y, Wang Y, Shao G, Zhang Q, Sun Y. Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. Biomater Sci. 2021;9(6):2279 [Crossref]
10- Akbarzadeh-Khiavi M, Torabi M, Olfati A, Rahbarnia L, Safary A. Bio-nano scale modifications of melittin for improving therapeutic efficacy. Expert Opinion on Biological Therapy. 2022;22(7):895 [Crossref]
11- Wong K. Integrated transcriptomics and proteomics data analysis identifies CDH17 as a key cell surface target in colorectal cancer. Computational Biology and Chemistry. 2023;105:107897 [Crossref]
12- Akbarzadeh Khiavi M, Safary A, Barar J, Ajoolabady A, Somi M, Omidi Y. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cell Mol Life Sci. 2020;77(6):997 [Crossref]
13- Mihanfar A, Yousefi B, Ghazizadeh Darband S, Sadighparvar S, Kaviani M, Majidinia M. Melatonin increases 5-flurouracil-mediated apoptosis of colorectal cancer cells through enhancing oxidative stress and downregulating survivin and XIAP. Bioimpacts. 2020;11(4):253 [Crossref]
14- Tong G, Luo Q, Pang X, Chen B, Lv G, Li X, Wang S. Retrospective Analyses of Complete Resection Combined with Systemic Chemotherapy and Targeted Therapy for Patients with Ovarian Metastases from Colorectal Cancer. Cancer Biotherapy and Radiopharmaceuticals. 2022;37(7):553 [Crossref]
15- Fathi M, Safary A, Barar J. Therapeutic impacts of enzyme-responsive smart nanobiosystems. Bioimpacts. 2019;10(1):1 [Crossref]
16- Rao J, Wan X, Tou F, He Q, Xiong A, Chen X, Cui W, Zheng Z. Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics. Front Mol Biosci. 2021;8 [Crossref]
17- Ghani S, Bahrami S, Rafiee B, Eyvazi S, Yarian F, Ahangarzadeh S, Khalili S, Shahzamani K, Jafarisani M, Bandehpour M, Kazemi B. Recent developments in antibody derivatives against colorectal cancer; A review. Life Sciences. 2021;265:118791 [Crossref]
18- Khelwatty S, Puvanenthiran S, Essapen S, Bagwan I, Seddon A, Modjtahedi H. HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. Cancers. 2021;13(4):638 [Crossref]
19- Swastha D, Varsha N, Aravind S, Samyuktha K, Yokesh M, Balde A, Ayilya B, Benjakul S, Kim S, Nazeer R. Alginate-based drug carrier systems to target inflammatory bowel disease: A review. International Journal of Biological Macromolecules. 2023;244:125472 [Crossref]
20- Roudi R, Barodabi M, Madjd Z, Roviello G, Corona S, Panahi M. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. Molecular & Cellular Oncology. 2020;7(5) [Crossref]
21- Akbarzadeh-Khiavi M, Farzi-Khajeh H, Somi M, Safary A, Barar J, Ansari R, Omidi Y. Eradication of KRAS mutant colorectal adenocarcinoma by PEGylated gold nanoparticles-cetuximab conjugates through ROS-dependent apoptosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2022;653:129890 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge